Navigation Links
FUISZ Announces Advances in Devices and Solid Dosage Form
Date:7/1/2010

MIAMI, July 1 /PRNewswire/ -- FUISZ today announced two medical technology advances.

First, FUISZ announced that it has received a notice of issuance from the United States Patent and Trademark Office for patent claims that cover a direct connection between prescribing physicians and blood analysis devices.  The invention allows for the health care provider to set the parameters of allowable analyte levels for each patient and enables simple notifications for any variance out of a pre-determined range. Joseph Fuisz, managing member of FUISZ stated, "These patent claims represents a quantum leap in the use of portable blood analyzers to provide a higher level of care for patients while reducing burdens on health care providers. We are in discussions with the blood analyzer industry for the licensing of this technology."

FUISZ also announced that it has filed a new patent in the field of solid oral Bioactive dosage forms. This novel system works to enhance or retard drug absorption.  It is particularly well suited to buccal, sublinqual and other forms of mucosal delivery including nano particles.  Joseph Fuisz commented, "This innovation can be readily adapted for use with existing products to improve control of drug absorption.  It will be particularly well received in the opiate market where controlling relative absorption of opiates and agonists is so critical.  This technology draws upon our deep knowledge of quick dissolve dosage forms and applies that knowledge in a broad manner to all solid dosage forms."

FUISZ is a family owned company. Fuisz principals Richard Fuisz, M.D. and Joseph Fuisz, Esq. are named inventors on or owners of hundreds of patents and patent applications. These patents span several fields: drug delivery, quick dissolve dosage forms including quick dissolve tablets, thin films, slow dissolve sheets, conventional oral dosage units, opiate abuse resistance, women's health, electronic mail, e-commerce, and tobacco. The company is based in Miami, Florida. www.fuisz.com.


'/>"/>
SOURCE FUISZ
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Fuisz Tobacco Announces Clinical Study Results for Fuisz Tobacco Sheet Strip; Super Enhanced Bioavailability of Nicotine From Its Tobacco Sheet Strip Supports Efficacy of Low Dose Tobacco Product
2. Fuisz Pharma Announces Novel Anti Abuse System for Opiates
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
5. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
6. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
7. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
8. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
9. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
10. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
11. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... India , February 8, 2016 ... a new market research report "Ablation Technologies Market by ... (Csardiovascular, Cancer, Pain Management, Cosmetic Surgery, Ophthalmology, Gynecology) - ... studies the global market over the forecast period of ... $4.44 Billion by 2020, at CAGR of 10.5% from ...
(Date:2/8/2016)... Kan. , Feb. 8, 2016 /PRNewswire/ ... organization that formerly specialized in the development ... recently announced that it has divided its ... Capital. While Nueterra Capital will continue the ... services, NueHealth will operate a national system ...
(Date:2/8/2016)... , Feb. 8, 2016  A research team ... scientists has discovered details of how the abnormal breakage ... a particularly aggressive form of acute lymphoblastic leukemia (ALL). ... which genetic mutations trigger overproduction of immature cells, called ... The discoveries of the malfunction underlying the type called ...
Breaking Medicine Technology:
(Date:2/8/2016)... Park, KS (PRWEB) , ... February 08, 2016 , ... ... a leader in Mole removal products. , Moles are derived from a cluster of ... appear in all the wrong places and create a lifetime of embarrassment. Historically, ...
(Date:2/8/2016)... ... , ... Guruji Mahendra Kumar Trivedi is offering 3 days of accelerated personal ... birthday on February 10th. During this time, people can achieve better health, greater ... people from over 40 different countries as an “ordinary man with an extraordinary gift.” ...
(Date:2/8/2016)... ... ... According to research by the National Association of Dental ... certified or obtain continuing education. To increase patient awareness of the lack of ... to inform dentists and patients about the possible lack of skills and knowledge ...
(Date:2/7/2016)... (PRWEB) , ... February 07, 2016 , ... Women's Excellence ... National Wear Red Day. National Wear Red Day is the first Friday each ... Heart disease and stroke cause 1 in 3 deaths among women each year – ...
(Date:2/7/2016)... AZ (PRWEB) , ... February 07, 2016 , ... ... Neck and Facial Plastics, has added Kybella® to his medical and surgical expertise. ... a newly approved FDA injectable medication used as a non-surgical alternative for reduction ...
Breaking Medicine News(10 mins):